

CONCORD DRUGS LIMITED

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To.

Date: 30.05.2022

BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2022

Ref: Our Company's letter dated 16.05.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 30.05.2022 at 4:00 p.m. at the registered office of the company the following were considered and approved:

- 1. Audited financial results for the quarter and year ended 31.03.2022. (Enclosed)
- 2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022. (Enclosed)

The meeting concluded at 08.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely, For Concord Drugs Limited

1

S. Nagi Reddy

Chairman & Whole time Director

DIN: 01764665



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

	STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS	FOR THE QUART	ER ENDED 31st	March 2022		
						[Rs. in Lak
			Quarterly ended		Year 6	ended
articu	ars	31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-2
I	Revenue from Operations	(Audited)	(unAudited)	(Audited)	(Audited)	(Audited)
	a. Net sales from Operations			200000000000000000000000000000000000000		
	b. Other Operating Income	1,546.46		834.63	5,895.648	5,135.7
II	Other Income	2.36	2.77	2.152	10.08	9.4
Ш	Total Revenue (I+II)	1,548.82	1,346.93	836.78	5,905.73	
IV	Expenses	1,510.02	1,540.93	030.78	5,905.73	5,145.1
	a.Cost of Material Consumed	1,065.71	1,065.86	552.782	444444	
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-193.07	15.75	42.560	4,441.147	4,049.1
	c. Employees Benefit Expenses	160.10	120.30		- 231.057	168.6
	d. Finance Costs	23.45	18.31	92.290	489.099	375.5
	e. Depreciation and Amortisation expense	37.10	29.51	27.486	168.075	142.0
	f. Other expenses	447.99	(T) (S) (S) (S) (S)	33.223	176.451	136.5
	Total Expenses	1,541.29	39.39	74.356	637.210	220.3
	Profit/ (Loss) before Exceptional Item and tax (III-IV)	7.53	1,289.12	822.70	5,680.92	5,092.2
V	Exceptional Items	7.33	57.82	14.087	224.81	52.8
VI	Profit/ (Loss) before tax (V-VI)	7.53	57.00	23.981	•	376.3
VII	Tax Expense:	4.80	57.82 15.68	38.068	224.805	429.2
III	a. Current tax	5.14	9.56	4.501	65.37	101.0
0	b. Deferred tax charge/credit	-0.34	2000	0.155	67.12	47.0
IX	Profit/ (Loss) for the period (VII-VIII)		6.12	4.346	1.75	53.9
X	Other Comprehensive Income	2.73	42.14	33.567	159.43	328.1
	Items that will not be reclassified to profit or loss			V-		
	Total Comprehensive Income for the world of	-	120	1000		-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	2.73	42.14	33.567	159.435	328.1
ΧI	Paid-up equity share capital	277/05/5			139,433	340.1
nool .	(Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38	874.3
	Other Equity	0.000	0. 555757000			
XII	Earnings per share (of Rs. 10 each)	1,961.68	1,958.95	1,802.249	1,961.68	1,802.24
III	a. Basic (in Rs)			- 1		
		0.03	0.48	0.38	1.82	3.7
	b. Diluted (in Rs)	0.03	0.48	0.38	1.82	3.7
tes:						-
1	The finnacial results of the company hav been prepared in accordance with the Indian Acc	counting Standar	ds (Ind AS) preso	ribed under sec	tion 133 of the C	ompanies Ac
	2013, read with the relevant rules issued there under.					
2	The above standalone financial results as reviwed by the audit committee have been applied to the committee have been app	roved by Board o	f Directors at its	meeting held or	30th May ,2022	
3	Figures of the corresponding previous periods are regrouped and reclassified wherever co	onsidered necess	ary to correspon	d with current p	eriod's presentat	ion.
4	The results are also available on the webiste of the Company www.concorddrugs.in		oruge			
		Conco	В	y Order of the B or Concord Dru	gs Limited	-
ce: H	yderabad	10	/*/	5. Nan Yw		
	January	1 X /	M	anaging Directo	N# 1	





CONCORD DRUGS LIMITEI

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

Audited Balance sheet as at 31st March , 2022 Rs in Lakhs					
Particulars	Note	As At March 31, 2022	As At March 31, 2021		
ASSETS					
Non-current assets					
(a) Property, plant and equipment	3	1,332.92	1,319.1		
(b) Capital Work-in Progress	3	55.39			
(b) Investment property	3	63.95	63.9		
Financial assets					
(a) Loans & Advances	5	3.19	2.6		
Other Non current assets	4	5.25	2.0		
Fotal Non - Current Assets		1,455.45	1,385.7		
Current Assets					
nventories	7	4 740 00	1 0222		
Financial assets	/	1,748.99	1,187.1		
(a) Investments					
(b) Trade receivables	6	2,285.85	2,072.8		
(c) Cash and cash equivalents	8	4.44	2,072.8		
(d) Bank balances other than (c) above	8	2.10	2.1		
(e) Other Current Financial Assets	9	10.07	4.4		
Other current assets	10	137.61	332.4		
Total Current assets		4,189.07	3,602.5		
Total Assets		5,644.513	4,988.7		
EQUITY AND LIABILITIES					
Equity					
quity share capital	11	874.38	874.3		
Other equity	12	1,961.68	1,802.2		
otal Equity		2,836.06	2.676.6		
otal Equity		2,830.00	2,676.6		
Non-current liabilities					
inancial Liabilities					
(a) Borrowings (b) Trade payables	13	248.26	375.1		
Deferred tax liabilities, net	14	65.03	67.6		
Provisions	14	65.92 208.38	67.6 208.3		
Sovernment Grants	13	200.30	36.9		
otal Non-current liabilities	1	522.56	688.0		
urrent liabilities					
inancial liabilities					
(a) Borrowings	16	1,395.17	922.2		
(b) Trade payables	17	717.88	314.7		
(c) Other Current financial liabilities	18				
Current tax liabilities, net	15	67.13	47.0		
Other current liabilities	19	105.72	339.5		
otal Current liabilities		2,285.90	1,623.5		
otal liabilities		2 909 45	2 244 61		
otal labilities		2,808.45 5,644.513	2,311.65 4,988.2		

Concord Drugs Limited

Chartered Accountants FRN- 011330s

SD/-

B.Surya Prakasa rao

Partner Mno-205125 Place: Hyderabad Date: 30.05.2022

5. No may S. Nagi Reddy
Managing Director

DIN:01764665

5- Koni Reddy Koni Reddy Seelam **Executive Director** DIN: 02829319





CONCORD DRUGS LIMITED

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

Statement of Cash flow for the year ended 31st Marc	h , 2022	R	s in Lakhs	
Particulars	As		As a	t
	March 3	1, 2022	March 31	, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES Profit Before Tax		200000000000000000000000000000000000000		/ 5765 1
Adjustments for :		224.805		429.2
Profit on sale of ASSets				
Depreciation and amortisation expense	176.45			126.5
Finance costs	141.33			136.5
Interest income	(1.23)			124.5
Provision for Gratutiy	(1.23)			(0.8
· ·		317		
Operating profit before working capital changes		541.36		689.4
Changes in working capital: (Refer Note 40)		341.30		089.4
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables	(213.04)		471.79	
Loans and Advances	(0.55)		50.98	
Other Non Current assets	-		37.85	
Inventories	(561.81)		455.94	
Other Current assets	194.87		29.71	
Other bank balances			0.49	
Other Current financial Assets	(5.66)		(0.29)	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	403.11	1	(964.85)	
Borrowings		1		
Other current financial liabilities	*			
Other current liabilities	-233.81	- 1		
Current tax liabilities, net Provisions	20.06	- 1	35.16	
Deferred tax on amalgamation	5¥1		(597.60)	
Cash generated from operations		144.54		200.5
Net income tax paid		144.54		208.64
Net cash flow from operating activities (A)	-	(67.12)	-	(47.07
B. CASH FLOW FROM INVESTING ACTIVITIES		77.419		161.57
Capital expenditure on fixed assets, including capital advances	245.64			
(Refer Note (iii) below)	-245.61		(367.40)	
Proceeds from maturiy of fixed deposits			- 1	
- Others	1.23		0.81	
Net cash (used in) / flow from investing activities (B)	1.23	(244.386)	0.61	(366.59
C. CASH FLOW FROM FINANCING ACTIVITIES		(244.300)		(300.33
Proceeds from issue of equity shares			-	
Finance costs	-141.33	1	(124.53)	
Repayment of Borrowings	-126.85		(27.42)	
Repayment of short term Borrowings	472.96		367.92	
Govt Grants	-36.92		(8.61)	
Other equity Adjustment			- 1	
let cash flow (used in) financing activities (C)		167.861		207.36
let (decrease) in Cash and cash equivalents (A+B+C)		0.89		2.34
ash and cash equivalents at the beginning of the year		3.546		1.21
Effect of exchange differences on translation of foreign		840	1	14
currency Cash and cash equivalents			1	
ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises:		4.44		3.55
alances with Banks		0.50		0.08
Others		3.94		3.46
				3.40

For Pundarikashyam And Associates

Chartered Accountants Firm Registration No.:011330S

SD/-

B.Surya Prakasa Rao

Partner M.No : 205125

Place: Hyderabad Date: 30.05.2022 For and on behalf of the Board of Directors of Concord Drugs Limited

CIN: L24230TG1995PLC020093

S. Nagi Reddy Managing Director DIN:01764665 5. Koni Red by Koni Reddy Seelam

Executive Director DIN: 02829319



CONCORD DRUGS LIMITED

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

	The same and salvey to 243, brainfining party village the			oozozz, rolangana
	Audited Statement Of Standalone Profit and Loss for the Particulars	Note	ended 31st March '22 As at March 31,2022	Rs in Lakhs As at March 31, 2021
ı	Revenue from Operations	Note	As at Watch 31,2022	As at Warch 31, 2021
	a. Net sales from Operations	20	5,895.648	F 12F 70
П	Other Income	21	10.082	5,135.70
Ш	Total Revenue (I+II)	**	5,905.730	9.46 5,145.16
IV	Expenses			
IV	a.Cost of Material Consumed			8 2 950 V.S
	10 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	22	4,441.147	4,049.15
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-231.057	168.67
	c. Employees Benefit Expenses	24	489.099	375.55
	d. Finance Costs	25	168.075	142.03
	e. Depreciation and Amortisation expense	3	176.451	136.53
	f. Other expenses	26	637.210	220.35
	Total Expenses		5,680.92	5,092.28
	Profit/ (Loss) before Exceptional item and tax (III-IV)		224.805	52.88
V	Exceptional Items			376.32
VI	Profit/ (Loss) before tax (V+VI)		224.805	429.20
VII	Tax Expense:		65.3704	101.03
VIII	a. Current tax		67.1212	47.07
	b. Deferred tax charge/credit		-1.7508	53.96
IX	Profit/ (Loss) for the period (VII-VIII)		159.4347	328.17
X	Other Comprehensive Income			
	Items that will not be reclassified to profit or loss		i.e.	
	Total Comprehensive Income for the period (comprising			
	profit and other comprehensive income for the period) (IX+X)		159.435	328.17
ΧI	Paid-up equity share capital		874.375	874.38
	(Face value of the share- Rs. 10 each)		190 (051.5)	
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		1.82	3.75
	b. Diluted (in Rs)		1.82	3.75

For Pundarikashyam and Associates

Chartered Accountants

FRN- 011330S

SD/-

B.surya Prakasa Rao

Partner

Mno-205125

Place: Hyderabad Date: 30.05.2022

For and on behlaf of the Board of Directors of **Concord Drugs Limited**

S. Nagi Reddy

Managing Director

5. Nan Rudby

DIN:01764665

5. Koni Reddy

Koni Reddy Seelam

Executive Director

DIN: 02829319

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA. E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To, BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001 Date: 30.05.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Nagi Reddy, Chairman & Whole time Director of Concord Drugs Limited hereby declare that the statutory Auditors of the company, M/s. Pundarikashyam and Associates, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely, For Concord Drugs Limited

5. Nost Rusty

S. Nagi Reddy Chairman & Whole time Director

DIN: 01764665



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar, Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail: info@pkas.in / infoong@pkas.in GSTIN: 36AAJFP6218J1ZY

Branches: 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12. 2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

- We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31,2022('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
- 2. This statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations. Our responsibility is to express anopinion on the Statement based on our audit of such interim consolidated financial statement.
- 3. We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

- 4. In our opinion and to the best of our information and according to the explanations given to us, the statement
 - a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - b gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2022.

For Pundarikashyam and Associates

HYDERABAD

Chartered Accountants

FRN: 011330S

B.Surya Prakasa Ra

(Partner) MNo: 205125

UDIN: 22205125AJXVOC7149

Place: Hyderabad Date: 30.05.2022.